Based Preventive Controls for Food for Animals; Draft Guidance for Industry; Availability’’ that appeared in the Federal Register of January 23, 2018. The document announced the availability of a draft guidance for industry #245 entitled “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals.” The document was published with the incorrect docket number. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy and Planning, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver Spring, MD 20993–0002, 301–796–9115.

SUPPLEMENTARY INFORMATION: In the Federal Register of Tuesday, January 23, 2018 (83 FR 3163), in FR Doc. 2018–01126, on page 3163, the following correction is made:

1. On page 3163, in the first column, in the header of the document, the docket number is corrected to read “FDA—2018–D–0388”.


Lisa Kux,
Associate Commissioner for Policy.

[FR Doc. 2018–02181 Filed 2–2–18; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2017–N–2428]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Animal Drug Adverse Event Reporting and Recordkeeping

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by March 7, 2018.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202–395–7285, or emailed to oira_submission@omb.eop.gov. All comments should be identified with the OMB control number 0910–0284. Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–7726, PRASstaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.


OMB Control Number 0910–0284—Extension

With regard to adverse events and product/manufacturing defects associated with approved new animal drugs, section 512(l) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360b(l)) requires applicants with approved new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) to establish and maintain records and reports of data relating to experience with uses of such drug, or with respect to animal feeds bearing or containing such drug, to facilitate a determination under section 512(e) as to whether there may be grounds for suspending or withdrawing approval of the NADA or ANADA under section 512(e) or 512(m)(4). Sections 511(e)(3) and 512(e)(2) of the FD&C Act (21 U.S.C. 360ccc(e)(3) and 360b(e)(2)) require that applicants with conditionally approved new animal drug applications (CNADAs) maintain adequate records and make reports in accordance with a regulation or order issued under section 512(l). Finally, section 512(m)(5) of the FD&C Act requires an applicant for a license to manufacture animal feeds bearing or containing new animal drugs to maintain adequate records and make reports “as the Secretary may by general regulation, or by order with respect to such application, prescribe on the basis of a finding that such records and reports are necessary in order to enable the Secretary to determine” whether there may be grounds for suspending or withdrawing approval of the new animal drug under section 512(e) or a license to manufacture animal feeds bearing or containing new animal drugs under section 512(m)(4).

Section 514.80 of our regulations (21 CFR 514.80) sets forth the recordkeeping and reporting requirements for applicants and nonapplicants of approved NADAs and ANADAs. Section 510.301 of our regulations (21 CFR 510.301) sets forth the recordkeeping and reporting requirements for licensed medicated feed manufacturing facilities.

Recordkeeping and reporting requirements for applicants of approved NADAs and ANADAs. Section 514.80 requires applicants to keep records of and report to us data, studies, and other information concerning experience with new animal drugs for each approved NADA and ANADA. Following complaints from animal owners or veterinarians or following their own detection of a problem, applicants are required to submit adverse event reports and product defect reports under § 514.80(b)(1), (b)(2)(i) and (ii), (b)(3), and (b)(4)(iv)(A) on Form FDA 1932. Form FDA 1932a (the voluntary reporting form) is used by veterinarians and the general public to submit adverse event reports, product defects, and lack of effectiveness complaints directly to FDA. Form FDA 2301 is used by applicants to submit the required transmittal of periodic reports (§ 514.80(b)(4)); special drug experience reports (§ 514.80(b)(5)(i)); promotional material for new animal drugs (§ 514.80(b)(5)(ii)); and distributor statements (§ 514.80(b)(5)(iii)). We review the records and reports required in § 514.80 and the voluntary reports to facilitate a determination under section 512(e) of the FD&C Act as to whether there may be grounds for suspending or withdrawing approval of the new animal drug. We have made minor editorial revisions to Form FDA 1932a to clarify how to report adverse drug events associated with compounded products using that form. Submitters are already reporting adverse event reports associated with compounded products on Form FDA 1932a. The clarifications include: the addition of a new question, “Is this a compounded product?”; the addition of a new field to allow the submitter to provide product strength, “Strength of Active Ingredient(s)”; modifying the title of the existing field requesting the name of manufacturer, so that it reads, “Name of Manufacturer or Compounding Pharmacy/Compounder of Suspected Product”; and a request for contact information for the manufacturer or compounding pharmacy.

We estimate that these changes will not change the average amount of time necessary to complete the form.
Recordkeeping and reporting requirements for applicants of CNADAs. As noted, sections 571(e)(3) and 512(e)(2) of the FD&C Act require that applicants for CNADAs maintain adequate records and make reports in accordance with a regulation or order issued under section 512(l) of the FD&C Act. Moreover, section 512(l) requires submission of such information as required “by general regulation, or by order.” Conditional approval letters explicitly establish an order requiring the submission of postmarketing information in accordance with the requirements of § 514.80. Applicants submit adverse event reports and product defect reports on Form FDA 1932.

Recordkeeping and reporting requirements for licensed medicated feed manufacturing facilities. Section 510.301 requires a licensed medicated feed manufacturer to keep records of and report to us information concerning experience with animal feeds bearing or containing approved new animal drugs. Under § 510.301(a), a licensed medicated feed manufacturer must immediately report to us information concerning any mixup in the new animal drug or its labeling; any bacterial contamination; any failure of one or more distributed batches of a drug to meet the specifications established for it. Under § 510.301(b), a licensed medicated feed manufacturer must report to us within 15 working days of receipt of information concerning any unexpected side effect, injury, toxicity, or sensitivity reaction or any unexpected incidence or severity thereof, and any unusual failure of the new animal drug to exhibit its expected pharmacological activity. OMB initially approved the information collection provisions of § 510.301 under control number 0910–0012. That approval was subsequently consolidated into this collection in 2004. We reviewed the records and reports required by § 510.301 to facilitate a determination as to whether there may be grounds for suspending or withdrawing approval of the new animal drug under section 512(e) of the FD&C Act, or grounds for revoking a license to manufacture medicated feed under section 512(m)(4).

Since the consolidation of the 0910–0012 collection into this collection in 2004, we have included the estimated number of medicated feed adverse event reports as part of our estimate of the number of all mandatory adverse event reports for new animal drugs. To improve the clarity of our estimates, we have added a row to table 1, on which we separately report our estimates of medicated feed reports.

The continuous monitoring of approved NADAs, ANADAs, CNADAs, and animal feed bearing or containing new animal drugs affords the primary means by which we obtain information regarding potential problems with the safety and efficacy of marketed approved new animal drugs, as well as potential product/manufacturing problems. Postapproval marketing surveillance is important because data previously submitted to us may not be adequate as animal drug effects can change over time and less apparent effects may take years to manifest.

Description of respondents: Respondents to this collection of information are animal drug manufacturers with approved NADAs, ANADAs, or CNADAs, as well as licensed commercial feed mills and licensed mixer-feeders.

In the Federal Register of July 18, 2017 (82 FR 32829), FDA published a 60-day notice requesting public comment on the proposed collection of information. Although one comment was received, it was not responsive to the four collection of information topics solicited and therefore will not be discussed in this document.

FDA estimates the burden of this collection of information as follows:

### Table 1—Estimated Annual Reporting Burden

<table>
<thead>
<tr>
<th>Activity</th>
<th>FDA Form</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Total annual responses</th>
<th>Average burden per response</th>
<th>Total hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicated feed reports, § 510.301(a) and (b)</td>
<td>N/A</td>
<td>5</td>
<td>1</td>
<td>5</td>
<td>*0.25</td>
<td>1.25</td>
</tr>
<tr>
<td>Mandatory adverse event reporting, 21 U.S.C. 360b(j); § 514.80(b)(1); (b)(2)(i) and (ii); (b)(3); and (d)(4)(ii)A</td>
<td>1932</td>
<td>22</td>
<td>81</td>
<td>1,782</td>
<td>1</td>
<td>1,782</td>
</tr>
<tr>
<td>Voluntary adverse event reporting by veterinarians and the general public</td>
<td>1932a</td>
<td>197</td>
<td>1</td>
<td>197</td>
<td>1</td>
<td>197</td>
</tr>
<tr>
<td>Periodic drug experience reports, § 514.80(b)(4)</td>
<td>2301</td>
<td>200</td>
<td>8.11</td>
<td>1,622</td>
<td>16</td>
<td>25,952</td>
</tr>
<tr>
<td>Special drug experience reports, § 514.80(b)(5)(i)</td>
<td>2301</td>
<td>200</td>
<td>0.57</td>
<td>114</td>
<td>222</td>
<td></td>
</tr>
<tr>
<td>Submission of advertisements and promotional labeling, § 514.80(b)(5)(ii)</td>
<td>2301</td>
<td>200</td>
<td>20.12</td>
<td>4,024</td>
<td>2</td>
<td>8,048</td>
</tr>
<tr>
<td>Submission of distributor statements, § 514.80(b)(5)(iii)</td>
<td>2301</td>
<td>190</td>
<td>0.11</td>
<td>19</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>36,246.25</td>
</tr>
</tbody>
</table>

1. There are no capital costs or operating and maintenance costs associated with this collection of information.  
2. (15 minutes).

### Table 2—Estimated Annual Recordkeeping Burden

<table>
<thead>
<tr>
<th>Activity</th>
<th>Number of record-keepers</th>
<th>Number of records per record-keeper</th>
<th>Total annual records</th>
<th>Average burden per record-keeping</th>
<th>Total hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recordkeeping, § 510.301</td>
<td>5</td>
<td>1</td>
<td>5</td>
<td>4</td>
<td>20</td>
</tr>
<tr>
<td>Recordkeeping, 21 U.S.C. 360b(l) and § 514.80(e)</td>
<td>646.70</td>
<td>7.19</td>
<td>4,649.8</td>
<td>14</td>
<td>65,097</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>65,117</td>
</tr>
</tbody>
</table>

1. There are no capital costs or operating and maintenance costs associated with this collection of information.  
2. This estimate includes all recordkeeping by licensed medicated feed manufacturers under § 510.301.
3. This estimate includes all recordkeeping by applicants of approved NADAs, ANADAs, and CNADAs under § 514.80(e).

We base our reporting and recordkeeping estimates on our experience with adverse event reporting for approved new animal drugs and the number of reports received in the previous 3 years. Since the
DEPARTMENT OF HEALTH AND HUMAN SERVICES

Meetings Announcement for the Physician-Focused Payment Model Technical Advisory Committee Required by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)

ACTION: Notice of public meetings.

SUMMARY: This notice announces the 2018 meetings of the Physician-Focused Payment Model Technical Advisory Committee (hereafter referred to as “the Committee”) which will be held in Washington, DC. This meeting will include voting and deliberations on proposals for physician-focused payment models (PFPMs) submitted by members of the public. All meetings are open to the public.

DATES: The 2018 PTAC meetings will occur on the following dates:
- Monday–Tuesday, March 26–27, 2018, from 9:00 a.m. to 5:00 p.m. ET
- Thursday–Friday, June 14–15, 2018, from 9:00 a.m. to 5:00 p.m. ET
- Thursday–Friday, September 6–7, 2018, from 9:00 a.m. to 5:00 p.m. ET
- Monday–Tuesday, December 10–11, 2018, from 9:00 a.m. to 5:00 p.m. ET

Please note that times are subject to change. If the times change, registrants will be notified directly via email.

ADDRESSES: All PTAC meetings will be held in the Great Hall of the Hubert H. Humphrey Building, 200 Independence Avenue SW, Washington, DC 20201.


SUPPLEMENTARY INFORMATION:
1. Purpose: The Physician-Focused Payment Model Technical Advisory Committee (“the Committee”) is required by the Medicare Access and CHIP Reauthorization Act of 2015, 42 U.S.C. 1395ee. This Committee is also governed by provisions of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), which sets forth standards for the formation and use of federal advisory committees. In accordance with its statutory mandate, the Committee is to review physician-focused payment model proposals and prepare recommendations regarding whether such models meet criteria that were established through rulemaking by the Secretary of Health and Human Services (the Secretary). The Committee is composed of 11 members appointed by the Comptroller General.

2. Agenda. At each scheduled meeting, the Committee will hear presentations on PFPMs that are ready for Committee deliberation. The presentations will be followed by public comment and Committee deliberation. If the Committee completes deliberations, voting will occur on recommendations to the Secretary of Health and Human Services. There will be time allocated for public comment on agenda items. Documents will be posted on the Committee website and distributed on the Committee listserv prior to the public meeting. The agenda is subject to change. If the agenda does change, we will inform registrants and update the website.

3. Meeting Attendance. These meetings are open to the public. The public may also attend via conference call or view the meeting via livestream at www.hhs.gov/live. The conference call dial-in information will be sent to registrants prior to the meeting.

Meeting Registration: The public may attend the meetings in-person, participate by phone via audio teleconference, or view the meeting via livestream. Space is limited and registration is preferred in order to attend in-person or by phone. Registration may be completed online at www.regonline.com/PTACMeetings.

The following information is submitted when registering:
Name:
Company/organization name:
Postal address:
Email address:
A confirmation email will be sent to registrants shortly after completing the registration process.

4. Special Accommodations. If sign language interpretation or other reasonable accommodation for a disability is needed, please contact Angela Tejeda, no later than one week prior to the scheduled meeting. Please submit your requests by email to Angela.Tejeda@hhs.gov or by calling 202–401–8297.


Additional material for this meeting can be found on the ASPE PTAC website. For updates and announcements, please use the link to subscribe to the ASPE PTAC email listserv.